News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Yissum Ltd. and Eucalyptus Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases



1/8/2008 8:54:14 AM

JERUSALEM--(BUSINESS WIRE)--Yissum Ltd., the technology transfer company of the Hebrew University of Jerusalem, today announced that it has licensed an orally‚Äďavailable small molecule for several biological indications including the treatment of neurodegenerative diseases to Eucalyptus Ltd. The molecule is an antioxidant that overcomes the blood-brain barrier.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES